Musings post ADA Top takeaways from an eventful meeting

Research evidence excerpt

Musings post ADA Top takeaways from an eventful meeting

8 June 2026

Musings post ADA EquitiesHealthcare

Top takeaways from an eventful meeting Global

◆ The oral competition race is intensifying with Novo so far Morten Herholdt*

beating expectations and keeping the lead on a better label Global Life Sciences & Healthcare Analyst HSBC Bank plc

morten.herholdt@hsbc.com

◆ Impressive weight loss data presented, but the move is + 44 20 7992 4082

towards more holistic treatment of diseases Rajesh Kumar*

Senior Global Life Sciences & Healthcare Analyst

HSBC Bank plc

◆ The obesity pipeline is growing with new mechanisms coming rajesh4kumar@hsbcib.com

+44 20 7991 1629

Shubhangi Gupta*, PhD

Commercial takeaways – the gloves are off (Clinical trial takeaway on page 2): Global Life Sciences & Healthcare Analyst

The competitive language is sharpening, with both Eli Lilly and Novo Nordisk pushing HSBC Securities and Capital Markets (India) Private Limited

the positioning of their newly launched oral obesity drugs. Lilly is pointing to the Achieve- shubhangi.gupta@hsbc.co.in

+91 80 4555 2143

3 trial where Foundayo beat oral Wegovy head-to-head on HbA1c reduction (2.2% vs

1.4%) and weight loss (9.2% vs 5.3% for the higher dosages). Note that this is in

* Employed by a non-US affiliate of HSBC Securities (USA) Inc, and is

diabetes patients and against Rybelsus, an older version of oral Wegovy with less not registered/ qualified pursuant to FINRA regulations

bioavailability. Novo, in contrast, is highlighting oral Wegovy’s 16.6% weight loss in

obesity and a label with a simple food restriction against Foundayo’s dose

considerations if taken with statins and the neutralising impact the drug has on

contraception. They think the label explains Wegovy’s better performance in the market.